Research
When a study of an approved drug needs no permission
Not every clinical study needs federal clearance. A study of a medicine already on the market can be exempt, but only if five conditions all hold at once, and one of them is about risk rather than paperwork.
A claim that needs a rule behind it
Clinics and sellers describe themselves as running studies fairly often, usually with an approved medicine involved.
The natural question is whether that requires the federal clearance that a new compound would need. The answer is written down, and it is conditional.
A study of a medicine already lawfully on the market can be exempt from those rules. The exemption comes with five conditions, and the word governing them is all.
The default position
The applicability section states the rule before it states the exceptions.
Except as provided in that section, the part applies to all clinical investigations of products subject to the relevant drug approval provision or the licensing provisions for biological products.
So the starting point is coverage, and everything else is a carve-out that has to be earned.
Two of those carve-outs sit elsewhere: material shipped only for tests in glassware or laboratory animals, and a closed list of three diagnostic reagents. A companion article covers that lane.
The exemption, and its five conditions
The clinical investigation of a drug product that is lawfully marketed in the United States is exempt from the requirements of the part if all of five things apply.
First, the investigation is not intended to be reported to the agency as a well-controlled study in support of a new indication for use. Nor is it intended to support any other significant change in the labeling for the drug.
Second, where the drug is lawfully marketed as a prescription product, the investigation is not intended to support a significant change in the advertising for it.
Third, the investigation does not involve a route of administration, a dosage level, a patient population, or another factor of a particular kind. The disqualifying kind is one that significantly increases the risks associated with the drug, or decreases the acceptability of those risks.
Fourth, the investigation is conducted in compliance with the requirements for institutional review, and with the requirements for informed consent.
Fifth, the investigation is conducted in compliance with the section governing promotion of investigational drugs.
The third condition is where most of the weight sits
The first two conditions are about intent, and a company generally knows its own. The fourth and fifth are procedural, and either happened or did not.
The third is a judgment about risk, and it is written broadly on purpose.
It names four things that can defeat the exemption: the route of administration, the dosage level, the patient population, and any other factor.
And it has two halves that are not the same test. A factor that significantly increases the risks, or one that decreases the acceptability of the risks.
The second half covers a change that makes the same risk less worth running, which is the situation where a study moves a medicine toward a use with less to gain.
You cannot ask for a ruling you do not need
One short paragraph closes an obvious route to certainty.
The agency will not accept an application for an investigation that is exempt under this provision.
So a sponsor cannot file for reassurance. If the exemption applies, there is no application to make, and no letter that confirms it.
The rule does leave a channel open. On request, the agency will advise on the applicability of the part to a planned investigation, and it may issue guidance on its own initiative.
That is advice about scope rather than a permission, which is a distinction worth carrying into any claim that a study was cleared.
Two smaller carve-outs, and one refusal
Two further exemptions are worth naming because they show how narrow these doors are.
A clinical investigation involving the use of a placebo is exempt where the investigation does not otherwise require an application.
The other is not an exemption at all, and it is the only entry on the list phrased as a refusal.
A clinical investigation involving an exception from informed consent is not exempt from the requirements of the part.
The pattern is consistent with everything else in these rules. Consent is the requirement that does not get traded away for convenience.
Practice is a different carve-out from the exemption
A separate paragraph handles ordinary medical practice, and it is easy to conflate with the exemption above.
The part does not apply to the use in the practice of medicine, for an unlabeled indication, of an approved drug product or a licensed biological product.
That is not a study exemption. It is a statement that treating a patient off-label is not a clinical investigation in the first place, which matches the definition of experiment elsewhere in the same part.
The distinction matters when a clinic describes what it does. Treating patients and running a study are different activities with different rules, and using the word research does not settle which one is happening.
What the agency says it is looking for
A separate section states the objectives behind the review, and it explains why the requirements scale.
The primary objectives are, in all phases, to assure the safety and rights of subjects. In the second and third phases, they also include helping assure that the quality of the scientific evaluation is adequate to permit an evaluation of the drug's effectiveness and safety.
The consequence is stated plainly. Review of first-phase submissions focuses on assessing the safety of those investigations. Review at the later phases also assesses scientific quality, and the likelihood the work will produce data capable of meeting the statutory standards for approval.
How much information is needed depends on four named factors: the novelty of the drug, the extent to which it has been studied previously, the known or suspected risks, and the developmental phase.
None of those is a page count. They are reasons, and they are the same reasons a careful reader would use to decide how much evidence a claim needs.
The individual researcher, and the borrowed file
The same section addresses the person most likely to be described in a clinic's marketing: an individual who both initiates and conducts a study.
Where such a person uses, as a research tool, an investigational drug already covered by a manufacturer's application, they follow the same general format. If authorized by the manufacturer, they may ordinarily refer to that manufacturer's file for the technical information.
Where the drug is not covered by any manufacturer's application, the position changes sharply. That person is ordinarily required to submit all the technical information supporting the filing, unless it can be referenced from the scientific literature.
That is the practical difference between studying something a company has already characterized and studying something nobody has. The paperwork does not shrink because the researcher is small.
What to ask when someone says they are running a study
The rule gives a reader a usable sequence of questions, none of which requires a legal conclusion.
Is the substance lawfully marketed in the United States, since the exemption is only available for one that is.
What is the study meant to support. An intention to change labeling or, for a prescription product, advertising, takes it outside the exemption.
Is anything about the route, the dose level or the population different from ordinary approved use, since that is the condition doing most of the work.
Was there review board oversight and informed consent, which are conditions rather than good practice here.
And finally, whether the word study is describing an investigation at all, or is describing treatment. The rules treat those as different things even when the same clinic does both.
Key takeaways
- The investigational drug rules apply to all covered clinical investigations unless a specific carve-out applies.
- A study of a lawfully marketed drug is exempt only if all five stated conditions apply at once.
- Two conditions turn on what the study is meant to support: a labeling change, or advertising for a prescription product.
- The risk condition fails on either an increase in risks or a decrease in the acceptability of those risks, and names route, dose level and population expressly.
- Institutional review and informed consent are conditions of the exemption, not optional good practice.
- No application can be filed for an exempt investigation, though the agency will advise on whether the part applies.
- Review objectives are subject safety and rights in every phase, plus scientific quality at the second and third, with the amount of information scaled to novelty, prior study, known risks and phase.
Frequently asked questions
Does every clinical study need federal clearance?
No. A clinical investigation of a drug product that is lawfully marketed in the United States is exempt from the investigational drug requirements if all of five conditions apply. The exemption is unavailable for a substance that is not lawfully marketed, because the first words of the provision limit it to one that is.
What are the five conditions?
The investigation is not intended to be reported as a well-controlled study supporting a new indication, or any other significant labeling change. For a prescription product, it is not intended to support a significant advertising change. It does not involve a route of administration, dosage level, patient population or other factor that significantly increases the risks, or decreases their acceptability. It complies with the institutional review requirements. And it complies with the informed consent requirements and with the rules on promotion of investigational drugs.
Which condition is hardest to satisfy?
Usually the third, because it is a judgment about risk rather than a fact about paperwork. It names the route of administration, the dosage level, the patient population and any other factor. It fails on either of two tests: a significant increase in the risks, or a decrease in the acceptability of those risks.
Can a company file an application just to be safe?
No. The rule states that the agency will not accept an application for an investigation that is exempt under this provision. What is available is advice: on request the agency will advise on the applicability of the part to a planned clinical investigation, and it may issue guidance on its own initiative. Advice about scope is not a permission.
Is a study with an exception from informed consent ever exempt?
No. That is the one entry on the list written as a refusal rather than a carve-out. A clinical investigation involving an exception from informed consent is not exempt from the requirements of the part.
Is prescribing off-label a clinical investigation?
The rules say it is not. The part does not apply to the use in the practice of medicine, for an unlabeled indication, of an approved drug product or a licensed biological product. That is a statement that treatment is not an investigation, which is separate from the five-condition exemption for a study.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- 21 CFR 312.2 — Applicability, including the five-condition exemption for a lawfully marketed drug — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
- 21 CFR 312.22 — General principles of the IND submission — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
- 21 CFR 312.3 — Definitions and interpretations — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026